Testing effectiveness (Phase 2)Study completedNCT01915498
What this trial is testing
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Who this might be right for
Hematologic Neoplasms
Celgene 345